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Testicular cancer is one of the most treatable cancers, with a 10-year survival of more than
95%. Many patients will be long-term survivors and this disease strikes men in an important
phase of their lives, therefore the quality of life (QoL) among these patients is an area of par-
ticular interest. We aimed to study whether QoL in testicular cancer survivors depends on
the time since cancer diagnosis.
Methods
Data were collected from the EPSAM (Esposizioni postnatali e salute maschile) study, a
case-control study on patients with testicular cancer, diagnosed between 1997 and 2008 in
the province of Turin, Northern Italy, and interviewed between 2008 and 2010 (response
rate among cases 57%). Patients were contacted through their oncologist at the San Gio-
vanni Batista Hospital in Turin or through their general practitioner (GP) in the rest of the
Province of Turin. QoL was assessed cross-sectionally using the short form 12 (SF-12)
questionnaire, a generic short-form health survey that produces two summary scores, PCS
(physical component score) and MCS (mental component score), to evaluate physical and
mental health, respectively.
Results
Out of 234 study patients, 125 cases were seminomas and 109 cases were nonseminomas.
The mean age at diagnosis was 34.5 years. After adjusting for age, time since diagnosis
was not associated with PCS and MCS scores. Among nonseminomas, the median PCS
slightly increased (adjusted OR (odds ratio) for 5+ vs < 2 years since cancer diagnosis: 1.78
(1.17–2.73), p = 0.008) and MCS slightly decreased (adjusted OR per 1-year increase since
cancer diagnosis: 0.92, 95% CI: 0.82–1.05, p = 0.23) with time. Similar findings of no asso-
ciation between time since diagnosis and PCS and MCS were found when the analyses
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were restricted to the subgroup of cancer patients contacted through their oncologist, whose
response proportion was 82%.
Conclusion
In a study of testicular cancer patients interviewed cross-sectionally at 1 to more than 10
years since diagnosis, time since cancer diagnosis was not associated with QoL when we
considered all germ-cell testicular cancer patients together. When stratified by histology
type, we found certain evidence that nonseminoma cases report higher PCS over time
since cancer diagnosis.
Introduction
Testicular cancer represents 1–3% of all cancers among males [1–3]. Incidence peaks at around
30 years of age and testicular cancer is the most frequent tumor among young men [1–3].
Moreover, its incidence has been increasing over the last few decades in many populations [1].
Nowadays, testicular cancer is one of the most treatable cancers, with a 10-year survival rate of
more than 95% [4]. This disease strikes men in an important phase of their lives, which is
often characterized by the start of a career and/or a family [5]. Thanks to a successful treat-
ment, testicular cancer patients will be long-term survivors, therefore their quality of life is an
area of particular interest. Treatment for testicular cancer is based on three fundamental
options: surgery, radiotherapy and chemotherapy. Cancer treatment may lead to considerable
morbidity, including sexual and fertility dysfunction after resection of retroperitoneal lym-
phatic nodes [6]; renal, cardiovascular, neurological or pulmonary diseases after chemother-
apy; and gastrointestinal problems after radiotherapy [7–12]. Both radiotherapy and
chemotherapy increase the risk of second primary cancers [13]. Previous studies about quality
of life among testicular cancer survivors suggest that diagnosis and treatment may affect
patients’ physical, mental, social and emotional health [14–22].
We aimed to study whether the quality of life (QoL) in testicular cancer survivors differs
with time since cancer diagnosis, in other words, whether there are time-dependent effects of
the disease and treatment on the age-adjusted QoL. We do not know if the quality of life
changes with time after diagnosis, because there are no studies that measured QoL repeatedly
over time. In this study we did not have longitudinal data, nevertheless, we administered the
same questionnaire cross-sectionally to men diagnosed with testicular cancer from 2 to 10
years before. The study was carried out among the cases of the EPSAM case-control study and
took advantage of the fact that in the EPSAM study patients diagnosed between 1997 and 2008




The study population has been previously described [23, 24]. Between 2008 and 2010, a popu-
lation-based case-control study was conducted among testicular cancer patients diagnosed in
the Province of Turin, Italy, between 1997 and 2008. Cases were all listed in the regional Hos-
pital Discharge Registry (ICD-9 CM diagnostic code 186 for testicular cancer and ICD-9 CM
surgical procedure code 623–624 for orchiectomy) and were contacted using two approaches.
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Patients followed at the University Hospital San Giovanni Battista (now named “Città della
Scienza e della Salute di Torino”), the main hospital in the city of Turin, were contacted
through their oncologist. The other patients were contacted through their general practitioners
(345 GPs, 81% of the total number of contacted GPs, agreed to collaborate with the study).
Consistently with a population-based approach, patients who were not residents in the Prov-
ince of Turin were not included in the study. The same two sources were used to select the
controls, who are however not included in this study that focuses on QoL among the cases.
The study was approved by the local Ethical Committee and informed consent was obtained
from each subject. The current study is thus a prevalence study on QoL conducted in 2008–
2010 among all patients diagnosed with testicular cancer in the Province of Turin between
1997 and 2008. QoL was assessed at different time distances since diagnosis of testicular can-
cer: for 35 patients within 2 years since diagnosis, for 75 patients between 2 and 5 years since
diagnosis and for 124 patients more than 5 years since diagnosis. Response rates were 49%
among case-patients contacted through their GP, 82% among those contacted through their
oncologist with an overall response rate of 57% and in total 274 study patients. We obtained a
copy of the histological review for all cases, except one who was excluded from the study. Five
cases who were not born in Italy were excluded from the study. Furthermore, following a com-
plete-case approach, we excluded 25 cases who did not answer the questions related to QoL
from the study questionnaire. Finally, we restricted the study to germ-cell testicular cancers, so
14 cases of the non-germ-cell origin or spermatocyte seminomas were excluded, resulting in
125 seminoma cases and 109 non-seminoma cases (mixed tumors were classified as nonsemi-
nomas). Thus, the study analyses included 234 cases. The EPSAM study was approved by the
Ethical Committee (IRB) of the San Giovanni Battista Hospital–CTO/CRF/Maria Adelaide
Hospital (Turin, Italy). Informed consent was obtained from all individual participants
included in the study. All patients consented to the interviews in writing and the patients’
identities were protected by project id numbers in order to secure potential identification of
the patients.
Questionnaire data
QoL was assessed using the SF-12 (Short Form 12) generic health survey [25] that includes
twelve questions. It produces two summary scores, PCS (Physical Composite Score) and MCS
(Mental Composite Score), which evaluate the physical and mental health, respectively, rang-
ing from 0 to 100, where 100 represents the highest level of QoL. SF-12 does not target a spe-
cific age or disease group and is a shorter and alternative form of the SF-36 (Short Form 36)
[26].
Statistical analyses
Since MCS and PCS in our study were not normally distributed, data were reported as median
and inter-quantile range (IQR), and logistic quantile regression was used to estimate the asso-
ciation between time since diagnosis (considered both as categorical, <2, 2–5, 5+ years, and as
a continuous variable with a 1-year scale) and QoL scores (modeling the median of the PCS
and MCS [27, 28]). The calculated odds ratios reflect odds of being above the median for the
exposed compared to the unexposed. The logistic quantile regression was adjusted for age at
the compilation of the questionnaire, educational level (junior high school, high school and
university degree), residence (city of Turin, the rest of the province of Turin) and method of
contact of the case (oncologist or GP). Confidence intervals were obtained using bootstrap.
Linearity on the logit scale was checked using restricted cubic splines for time since diagnosis
and age at compilation.
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Stratified analyses by histological type (seminoma/ non-seminoma) were also conducted.
In order to evaluate the potential bias introduced by the low response proportion, we con-
ducted a sensitivity analysis restricted to cases contacted through their oncologist because of
the high response proportion (82%) in this group.
In addition, the QoL score means of the patients in our study were compared with those of
the general Italian population, using previously published age-stratified (5 groups: <24, 25–34,
35–44, 45–54 and 55+ years of age) means of PCS and MCS [29, 30].
All analyses were conducted using STATA statistical software (version 13, College Station,
TX: StataCorp LP).
Results
Descriptive characteristics are reported in Table 1. Out of 234 patients, 78 (33.3%) were con-
tacted through their oncologist and 156 (66.7%) were contacted through their GP. Regarding
the histological type, 125 cases (53.4%) were seminomas and 109 cases (46.7%) were non-semi-
nomas. The mean age at diagnosis was 34.5 years (aged between 16.4 and 57.3 years at diagno-
sis). The median time between diagnosis and compilation of the questionnaire was 5.3 years
Table 1. Descriptive characteristics of the cases included into the study.


















General practitioners 156 66.7
Hospital 78 33.3
Residence
City of Turin 92 39.3





Lower secondary school or less 85 36.3
Upper secondary school 95 40.6
University degree 54 23.1
https://doi.org/10.1371/journal.pone.0258257.t001
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(IQR: 2.7–8.2); The median PCS score was 54.2 (IQR: 50.0–55.9) and the median MCS score
was 50.2 (IQR: 40.9–55.1).
S1 Table reports mean age-specific PCS and MCS scores for cases included in the study and
general Italian population reported in the study by Kodraliu et al. [29]. The mean values of
PCS and MCS calculated in the subjects of our study are consistent with age-specific scores
among men of the general Italian population.
Table 2 reports the median and inter-quartile ranges of PCS and MCS, according to differ-
ent characteristics of the testicular cancer patients. After adjustment by age, none of the vari-
ables was associated with median MCS, while age at diagnosis, educational level and
histological type were associated with PCS.
Table 3 reports the estimated odds ratios of the median score in each category of time since
diagnosis vs the reference (<2 years) when time is considered as a categorical, and for one year
increase of time since cancer diagnosis when it is considered as a continuous variable. For
example, 1.11 represents the adjusted odds ratio of the median score when the time since diag-
nosis is larger than 5 years compared to the reference (<2 years), where the odds are defined
using the score instead of a probability, (PCS12-22.37)/(62.36-PCS12).
Table 4 reports the results stratified by histological type. Possible decline tendency of MCS
over time since diagnosis, can be noticed in nonseminomas (adjusted OR for 1-year increase:
0.92, 95% CI:0.82–1.05, p = 0.23), for which there was also a positive association between time
since diagnosis and PCS (for 5+ vs< 2 years 1.78, 95% CI: 1.17–2.73, p = 0.008; adjusted OR
for 1 year increase: 1.03, 95% CI:0.98–1.08, p = 0.17). Figs 1 and 2 show the predicted PCS and
MCS scores for the 25th, 50th and 75th quantiles by time since diagnosis in non-seminomas
cases. Sensitivity analyses revealed a limited impact of non-response on our results. When
analyses were restricted to the 78 cases contacted through their oncologist, results were consis-
tent with those reported in Table 3 for the full cohort (PCS: adjusted OR: 1.06; MCS: adjusted
OR: 1.00, for each 1-year increase in the time since diagnosis when considered as continuous).
Discussion
In a cross-sectional study of testicular cancer patients followed up for 1 to more than 10 years,
we did not find clear evidence of an association between time since cancer diagnosis and
patients’ QoL when we considered all germ-cell testicular cancer patients together. When the
analyses were stratified by histology type, we found some evidence of a possible increase in
PCS among nonseminomas. Although without clear statistical evidence, MCS among nonse-
minomas seems to be decreasing over time since cancer diagnosis.
A possible difference in changes in PCS and MCS over time by histology is difficult to
explain. It could be due to the ages at which nonseminomas and seminomas are diagnosed
(nonseminomas peak at around 25–30 years of age and seminomas at around 35 years of age)
and because of the difference in the therapeutic approach between the two histology groups.
Considering the different age peaks of testicular cancer, possible explanations for the mental
health decreasing in non-seminomas cases, may be explained by the fact that problems with
infertility and sexuality in testicular cancer survivors will be more discouraging for younger
instead of older men. Besides, the literature supports that younger cancer survivors show
greater anxiety and poorer QoL [31].
Quality of life among testicular cancer survivors has been a matter of interest for a long
time and to our knowledge, there are no previous studies that assessed the relationship
between time since testicular cancer diagnosis and patients’ QoL. Findings in our study,
regarding mental and physical health, are consistent with the scientific knowledge up to now.
Literature reviews [32–35] have shown that although testicular cancer survivors do not have
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Table 2. Physical and mental component scores distribution by cases’ characteristics.
Cases Median (IQR)
Characteristics N = 234 % PCS12 (IQR) MCS12 (IQR)
Overall score 54.18 (50.00–55.91) 50.24 (40.95–55.13)
1. Age at diagnosis (mean age: 34.5)
�24 33 14.1 55.70 (54.42–56.82) 48.04 (37.54–55.13)
25–34 87 37.2 54.21 (50.38–56.00) 50.67 (41.30–53.39)
35–44 75 32 53.54 (48.80–55.88) 49.94 (41.86–55.87)
45+ 39 16.7 53.55 (44.86–54.92) 49.98 (29.92–57.92)
p value^ 0.04 0.51
2. Age at compilation (mean age: 40.2)
�24 7 3 55.91 (54.74–57.26) 52.98 (31.83–55.87)
25–34 59 25.2 54.18 (51.03–55.91) 50.60 (44.21–54.68)
35–44 90 38.5 54.32 (51.50–56.02) 50.17 (41.86–55.10)
45–54 59 25.2 52.81 (47.97–55.24) 50.85 (36.46–55.87)
55+ 19 8.1 53.55 (41.32–55.40) 47.37 (29.43–55.96)
p value^ 0.30 0.67
3. Method of identification and contact
General practitioners 156 66.7 54.09 (50.52–55.91) 50.11 (40.60–55.09)
Hospital 78 33.3 54.14 (46.20–55.53) 50.67 (41.86–55.77)
p value^ 0.90 0.72
adjusted p value� 0.57 0.88
4. Histology type
Seminoma 125 53.4 54.18 (51.03–55.91) 50.24 (41.86–55.87)
Nonseminoma 109 46.6 54.07 (48.38–55.89) 50.58 (40.86–53.95)
p value^ 0.74 0.74
adjusted p value� 0.03 0.84
5. Education level
Lower secondary school or less 85 36.3 53.12 (46.65–54.31) 50.67 (40.25–55.87)
Upper secondary school 95 40.6 54.31 (50.51–56.44) 49.90 (37.54–54.32)
University degree 54 23.1 55.12 (52.83–55.91) 50.51 (43.06–56.87)
p value^ 0.08 0.58
adjusted p value� 0.003 0.86
6. Residence
City of Turin 92 39.3 54.19 (51.21–55.74) 50.34 (40.91–55.87)
Province of Turin 142 60.7 53.91(49.19–55.91) 50.29 (41.30–54.63)
p value^ 0.58 0.88
adjusted p value� 0.88 0.84
7. Time between diagnosis and compilation of the questionnarie
<2 35 15.3 54.18 (45.92–55.91) 51.14 (44.74–55.87)
2–5 75 31.9 53.82 (51.03–55.41) 49.94 (42.61–53.95)
5+ 124 52.8 54.13 (50.19–55.91) 49.98 (37.26–55.50)
p value^ 0.98 0.65
adjusted p value� 0.75 0.74
^Wald test for composite linear hypothesis after applying univariable quantile logistic regression.
� Adjusted for age at compilation.
https://doi.org/10.1371/journal.pone.0258257.t002
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serious disruptions to general health, however, they are more likely to experience mental
health impairment as fatigue, anxiety, sexual problems and fear of cancer recurrence.
Other studies [14, 22, 36] that assessed the QoL among testicular cancer survivors con-
cluded that QoL did not differ when compared with the age-matched general male population,
except for slightly lower scores for mental health. Finally, two case-control studies have found
that overall health status did not differ dramatically between cases and age-matched healthy
male controls from the general population, but they did find that patients who received che-
motherapy have lower PCS and MCS scores than those who did not [16, 17].
However, it is challenging to set in a context our results and make a comparison with previ-
ous research evidence. Previous studies have mainly used a wide range of different question-
naires to investigate the impact of chemotherapy, radiotherapy and acquired comorbidities on
patients’ QoL. Moreover, we aimed to assess specifically the effect of time since cancer
diagnosis.
The main two strengths of our study are: (i) its population-based design, (ii) the ability to
analyze time since cancer diagnosis using a validated generic health survey. In a large study
carried out to validate the SF-12 health survey in nine countries [30], SF-12 was proved to be a
practical alternative to the SF-36 survey, for purposes in which the focus is on overall physical
Table 3. ORs (odds ratios) and 95% confidence intervals (95% CI), estimated using logistic quantile regression, of median of PCS and MCS for time since cancer
diagnosis.
Years since diagnosis Cases, N = 234 PCS (Physical Composite Score) MCS (Mental Composite Score)
Categories N (%) Unadjusted Adjusted � Unadjusted Adjusted �
(50 quantiles) (50 quantiles) (50 quantiles) (50 quantiles)
<2 36(15.3) ref. ref. ref. ref.
2–5 75(31.9) 0.95 (0.70–1.31), p = 0.74 0.95 (0.69–1.31), p = 0.77 0.88 (0.50–1.54), p = 0.65 0.76 (0.42–1.38), p = 0.37
5+ 124(52.8) 0.98 (0.72–1.34), p = 0.91 1.11 (0.82–1.51), p = 0.49 0.86 (0.51–1.45), p = 0.57 0.71 (0.40–1.25), p = 0.23
1 year increase 0.99 (0.97–1.02), p = 0.83 1.01 (0.97–1.04), p = 0.59 0.97 (0.92–1.02), p = 0.29 0.96 (0.90–1.02), p = 0.18
� ORs (odds ratios) are adjusted for: age at compilation, educational level, residence and method of identification/contact.
https://doi.org/10.1371/journal.pone.0258257.t003
Table 4. ORs (odds ratios) and 95% confidence intervals (95% CI), estimated using logistic quantile regression of median of PCS and MCS for time since cancer
diagnosis of nonseminoma and seminoma cases.
Years since diagnosis Nonseminomas cases, N = 109 PCS (Physical Composite Score) MCS (Mental Composite Score)
Categories N (%) Unadjusted Adjusted� Unadjusted Adjusted�
(50 quantiles) (50 quantiles) (50 quantiles) (50 quantiles)
<2 19 (17.4) ref. ref. ref. ref.
2–5 33 (30.3) 1.21 (0.66–2.20), p = 0.53 1.29 (0.83–2.04), p = 0.25 0.70 (0.26–1.90), p = 0.48 0.74 (0.28–1.96), p = 0.55
5+ 57 (52.3) 1.41 (0.81–2.44), p = 0.22 1.78 (1.17–2.73), p = 0.008 0.52 (0.21–1.28), p = 0.15 0.62 (0.25–1.54), p = 0.30
1 year increase 1.02 (0.96–1.09), p = 0.50 1.03 (0.98–1.08), p = 0.17 0.90 (0.82–1.00), p = 0.04 0.92 (0.82–1.05), p = 0.23
Years after diagnosis Seminomas cases, N = 125 PCS (Physical Composite Score) MCS (Mental Composite Score)
Categories N (%) Unadjusted Adjusted� Unadjusted Adjusted
(50 quantiles) (50 quantiles) (50 quantiles) (50 quantiles)
<2 16 (12.8) ref. ref. ref. ref.
2–5 42 (33.6) 1.04 (0.70–1.54), p = 0.83 0.90 (0.53–1.51), p = 0.67 0.89 (0.37–2.13), p = 0.79 0.79 (0.29–2.16), p = 0.65
5+ 67 (53.6) 0.92 (0.63–1.33), p = 0.64 0.81 (0.48–1.38), p = 0.44 1.08 (0.47–2.47), p = 0.84 0.96 (0.35–2.63), p = 0.93
1 year increase 0.99 (0.95–1.02), p = 0.47 0.97 (0.92–1.03), p = 0.31 1.01 (0.94–1.09), p = 0.80 1.01 (0.91–1.12), p = 0.82
� ORs (odds ratios) are adjusted for: age at compilation, educational level, residence and method of identification/contact.
https://doi.org/10.1371/journal.pone.0258257.t004
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and mental health outcomes and when QoL is assessed together with several other research
hypotheses, like in the EPSAM study.
Our study had also some limitations. First, it has a cross-sectional and not a longitudinal
design, but it is still more informative, in terms of the change of QoL over time since diagnosis
than studies measuring QoL at the same follow-up time for all patients. Second, our approach
did not provide direct information on whether on average (irrespectively of time since diagno-
sis) the QoL of testicular cancer patients is higher or lower than the general population. In
other words, our study does not test whether testicular cancer patients have a decreased QoL,
Fig 1. Scatterplot and line plot of predicted response for the 25th, 50th and 75th quantile for PCS in
nonseminomas cases, on time between diagnosis and compilation of the questionnaire. The lines refer to a subject
with all categorical variables set at the reference values and aged 40 years at compilation of the questionnaire.
https://doi.org/10.1371/journal.pone.0258257.g001
Fig 2. Scatterplot and line plot of predicted response for the 25th, 50th and 75th quantile for MCS in
nonseminomas cases, on time between diagnosis and compilation of the questionnaire. The lines refer to a subject
with all categorical variables set at the reference values and aged 40 years at compilation of the questionnaire.
https://doi.org/10.1371/journal.pone.0258257.g002
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but only if their QoL changes with time since diagnosis. For the purpose of clarifying and bet-
ter explain our results, we compared QoL scores of our study cases with those of the general
Italian population. The age-specific PCS in our testicular cancer patients did not differ from
those of the general Italian population, but they had had a lower age-specific MCS. Further-
more, we faced a low response proportion (50%). A low response proportion is not uncom-
mon in QoL studies, but nevertheless, it can introduce severe bias if participation depends on
the quality of life of the patients. However, in a sensitivity analysis restricted to the patients
contacted through their oncologist, we found little evidence of an impact of non-response on
our study estimates.
Finally, we did not have access to the clinical charts of all testicular cancer patients so we
could not reconstruct the treatment and co-morbidity history of the patients in the years
between diagnosis and the participation in the study (this information was not asked in the
study questionnaire, as the study had mainly the aim of identifying risk factors for the occur-
rence of testicular cancer). It should be noted however that post-diagnostic co-morbidity status
and treatment are not confounders in our analysis but would have been rather mediators/
explanators for our findings.
Conclusions
Taking into account all the features mentioned above, to our knowledge, this is the first study
specifically studying time since cancer diagnosis in association with the QoL of testicular can-
cer patients. Our main findings suggest that QoL in terms of physical and mental scores did
not vary with time since diagnosis of testicular cancer, but may increase in PCS among
nonseminomas.
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